TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05325073

Intervention type: DRUG
Group type: OTHER
Intervention: Erythropoietin
Description: Erythropoietin
Study: NCT05116462

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 D1 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 D1 IV Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 or 6 mg/ml/min D1 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 or 6 mg/ml/min D1 IV Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 or 200 mg/m2 D1 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 or 200 mg/m2 D1 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg D1 IV Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 D1 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 D1 IV Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab paclitaxel
Description: 100 mg/m2 D1, 8, 15 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 100 mg/m2 D1, 8, 15 IV Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml D1 IV Q3W
Study: NCT04636060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eisen
Description: Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
Study: NCT05676281

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Together (Control)
Description: The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Together + Promotora Support
Description: The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Together + Parenting Training
Description: The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Togethers + Parenting Training + Promotora support
Description: The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~* 8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum
Study: NCT05073952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: Implants will be placed with a flap and a connective tissue graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flapless
Description: Implants will be placed with a flapless approach
Study: NCT05494645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Liposomal bupivicaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Liposomal bupivicaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Block
Description: Peripheral nerve block without Exparel
Study: NCT06309602

Intervention type: OTHER
Group type: OTHER
Intervention: Control / Standard Care
Description: Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
Study: NCT04820686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBR
Description: VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).

Intervention type: DRUG
Group type: OTHER
Intervention: VBR
Description: VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).

Intervention type: DRUG
Group type: OTHER
Intervention: AB-729
Description: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: SOC NrtI
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC NrtI
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Study: NCT06187779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower segment measurment
Description: Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
Study: NCT04482777

Intervention type: DRUG
Intervention: Corticosteriod for treated patients
Description: Drug given to some patients with autoimmune disease
Study: NCT04820686

Intervention type: DRUG
Group type: OTHER
Intervention: SOC NrtI
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Study: NCT04482777

Intervention type: DRUG
Intervention: Corticosteriod for treated patients
Description: Drug given to some patients with autoimmune disease

Intervention type: DRUG
Intervention: Corticosteriod for treated patients
Description: Drug given to some patients with autoimmune disease
Study: NCT05278533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioPlete™ Advanced Formula
Description: 2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
Study: NCT03418272

Intervention type: DIAGNOSTIC_TEST
Intervention: Culture/PCR Analysis
Description: Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis

Intervention type: DIAGNOSTIC_TEST
Intervention: Culture/PCR Analysis
Description: Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis
Study: NCT05702398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 1,000 μg retinyl palmitate twice a day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: 500 mg NAM twice a day for 6 months
Study: NCT05939635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided external oblique intercostal block (EOIB)
Description: Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block
Description: Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine patient-controlled analgesia (PCA)
Description: Morphine will be administered via PCA device for the first 24 hours after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine patient-controlled analgesia (PCA)
Description: Morphine will be administered via PCA device for the first 24 hours after surgery
Study: NCT05672823

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
Study: NCT03415061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin, Human 100 UNT/ML
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Study: NCT05226546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Description: PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after

Intervention type: OTHER
Group type: OTHER
Intervention: olfactory training
Description: The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training.
Study: NCT05702398

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Identical placebo pills twice a day
Study: NCT05023850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLIPB
Description: Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
Study: NCT06293716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL237 tablets
Description: CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL237 tablets
Description: CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVL237 placebo tablets
Description: CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Study: NCT05600361

Intervention type: DRUG
Group type: OTHER
Intervention: hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy
Description: In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
Study: NCT04217707

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre- and Post-Surgical Transgender Therapeutic Support Group
Description: Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
Study: NCT04710498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
Study: NCT06084533

Intervention type: DRUG
Intervention: [11C]-CS1P1
Description: Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.

Intervention type: DRUG
Intervention: [11C]-CS1P1
Description: Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
Study: NCT06485726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid 500 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05106595

Intervention type: DEVICE
Intervention: Bimanual Arm Trainer
Description: tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
Study: NCT06485726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05595551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention Aan Tafel in 1, 2, 3 euro
Description: The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card.
Study: NCT06362447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Injectable Solution
Description: Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
Study: NCT04836572

Intervention type: OTHER
Group type: OTHER
Intervention: 3M 1529 Adhesive Tape
Description: 5-12 hour adhesive wear
Study: NCT06265246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual Diet + Milk
Description: 1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual Diet + Yogurt
Description: 2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
Study: NCT04889807

Intervention type: OTHER
Intervention: measure of EtCO2 variation
Description: measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
Study: NCT05865067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The wait-list control group will be motivated to exercise at home (except for Yoga).
Study: NCT05419999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS mini CT
Description: During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Soterix 1x1 tDCS Mini CT
Description: Sham setting is used on the Soterix transcranial electrical stimulator

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Written Exposure Therapy (WET)
Description: An exposure-based, behavioral psychotherapy for PTSD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Description: An exposure-based, behavioral psychotherapy for PTSD.
Study: NCT06064643

Intervention type: OTHER
Intervention: Online Survey
Description: All participants will be asked to complete an online survey

Intervention type: OTHER
Intervention: Qualitative Interview
Description: 30 survey participants will take part in a single one-hour qualitative interview.

Intervention type: OTHER
Intervention: Bleed Diary
Description: 50 participants will complete a 30 day bleed diary
Study: NCT05649397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical manipulation
Description: provide a high velocity, low-amplitude manipulation to each subject's cervical spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: 15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
Study: NCT05862246

Intervention type: OTHER
Intervention: Clinical examination
Description: No intervention, only clinical examination

Intervention type: OTHER
Intervention: Clinical examination
Description: No intervention, only clinical examination